NasdaqGS:ABCLLife Sciences
AbCellera Biologics (ABCL) Is Up 6.8% After Announcing First Human Data Timeline For ABCL635
AbCellera Biologics recently announced that it will share interim Phase 1 data for ABCL635, its potential first-in-class non-hormonal antibody targeting the neurokinin 3 receptor for menopausal vasomotor symptoms, during its first-quarter 2026 earnings call on May 11, 2026.
This update marks the first clinical readout from AbCellera’s GPCR and ion channel platform, highlighting how its transition into a clinical-stage pipeline is beginning to be tested in humans.
We’ll now examine how the...